Registered title, quoted from ClinicalTrials.gov
Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 40 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 40
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
- Study siteChangzheng Hospital海军军医大学第二附属医院(长征医院)ShanghaiHospital page
- Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
- Study siteFirst Affiliated Hospital of Fujian Medical University福建医科大学附属第一医院FuzhouHospital page
- Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
- Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
- Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
- Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
- Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
- Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
- Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
- Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
- Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
- Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
- Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
- Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
- Study siteSouthwest Hospital, Army Medical University陆军军医大学第一附属医院(西南医院)ChongqingHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteTianjin First Central Hospital天津市第一中心医院TianjinHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteXijing Hospital空军军医大学西京医院Xi'anHospital page
- Study siteXinqiao Hospital, Army Medical University陆军军医大学第二附属医院(新桥医院)ChongqingHospital page
- Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07896590, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Has received at least one prior line of systemic therapy containing anti CD20 monoclonal antibody.
Inclusion criterion 3
Prior disease refractory to BTK inhibitor or BCL 2 inhibitor treatment.
Exclusion criterion 5
Has measurable disease per 2014 Lugano classification.
Inclusion criterion 5
Received anti cancer therapies within 2 weeks before first investigational product dose.
Exclusion criterion 2
Second primary malignancy within 2 years before screening.
Exclusion criterion 8
Active infection requiring intravenous anti infective therapy; positive HIV antibody; active HBV/HCV.
Exclusion criterion 14
Females must have negative serum pregnancy test. Participants must use effective contraception during the study.
Inclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07896590, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Aged ≥18 years, male or female.
- Histopathologically confirmed marginal zone lymphoma (including splenic, nodal, extranodal MZL subtypes).
- Has received at least one prior line of systemic therapy containing anti CD20 monoclonal antibody.
- Disease is relapsed or refractory.
- Has measurable disease per 2014 Lugano classification.
- Meets required laboratory thresholds for hematological, liver, and renal function
- Females must have negative serum pregnancy test. Participants must use effective contraception during the study.
- Able to comply with study procedures and assessments.
- Voluntarily provides written informed consent.
Exclusion Criteria:
- Confirmed transformation into an aggressive lymphoma.
- Received anti cancer therapies within 2 weeks before first investigational product dose.
- Chronic corticosteroid for anti cancer purpose during screening.
- Any investigational agent within 4 weeks before study treatment; concurrent participation in other investigational therapeutic trials.
- Prior disease refractory to BTK inhibitor or BCL 2 inhibitor treatment.
- Prior allogeneic hematopoietic stem cell transplantation or CAR T therapy.
- central nervous system / meningeal lymphoma involvement.
- Second primary malignancy within 2 years before screening.
- Uncontrolled clinically significant cardiovascular disease.
- Thromboembolic events within 6 months prior to first dose.
- Grade 3 4 active bleeding within 2 months before screening or significant bleeding diathesis.
- Clinically significant gastrointestinal malabsorption, major gastrointestinal resection.
- Major surgery or severe trauma before first dose or planned selective surgery during study.
- Active infection requiring intravenous anti infective therapy; positive HIV antibody; active HBV/HCV.
- Severe interstitial lung disease, pneumoconiosis, radiation or drug induced pneumonitis.
- Active autoimmune disease requiring systemic therapy.
- Psychiatric/cognitive disorders.
- Substance abuse.
- Use of strong CYP3A/P gp inhibitors / inducers within 5 drug half lives before dosing or planned concomitant intake of strong modulating agents/food during study.
- Received live / live attenuated vaccines within 4 weeks prior to first study drug dose.
- Known severe hypersensitivity/anaphylaxis to investigational products, drug class agents or tablet excipients.
Quoted from ClinicalTrials.gov, NCT07896590, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07896590, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.